The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
Patients (and replacements) will be randomly selected by a raffle.
All participants should be 18 years of age or older and agree to participate in the study after due clarification.
Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.
- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.
Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.
Patients with infection or autoimmune diseases.